Advertisement
Advertisement
Advertisement

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH12-06-0377
Issue: 2013: 109/1 (Jan) pp. 1–173
Pages: 93-101

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention

A systematic review and meta-analysis

D. Aradi (1), A. Komócsi (1), A. Vorobcsuk (1), V. L. Serebruany (2)

(1) University of Pécs, Heart Institute, Division of Interventional Cardiology, Hungary; (2) HeartDrug™ Research LLC, Johns Hopkins University, Towson, Maryland, USA

Summary

Administration of a P2Y 12 -receptor antagonist in addition to aspirin is mandatory in patients with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI) to reduce the occurrence of thrombotic events; however, their impact on mortality and stroke is unclear. We aimed to evaluate the influence of moderate (clopidogrel) or potent (prasugrel/ticagrelor) P2Y 12 -receptor inhibition on major cardiovascular outcomes among patients with ACS or undergoing PCI. Systematic literature search was performed to find randomised, controlled clinical trials comparing the clinical impact of clopidogrel with placebo or prasugrel/ticagrelor versus clopidogrel. Outcome measures included cardiovascular death, myocardial infarction (MI), total stroke and intracranial haemorrhage (ICH). Random-effects model with Mantel-Heanszel weighting was used to pool outcomes into a meta-analysis. Four studies comparing clopidogrel with placebo and five trials comparing clopidogrel with new P2Y 12 -receptor inhibitors were identified including a total of 107,473 patients. Compared to placebo, clopidogrel reduced the risk of cardiovascular death (odds ratio [OR]: 0.93; 95% confidence interval [CI]: 0.87–0.99, p=0.02), MI (OR 0.80; 95%CI 0.74–0.88, p<0.00001) and stroke (OR 0.84; 95%CI 0.72–0.97, p=0.02), without influencing risk for ICH (OR 0.96; 95%CI 0.69–1.33, p=0.79). Treatment with prasugrel/ticagrelor provided additional benefit over clopidogrel regarding cardiovascular mortality (OR 0.86; 95%CI 0.78–0.94, p=0.002) and MI (OR: 0.83; 95%CI 0.74–0.93, p<0.001), but no advantage in stroke (OR: 1.06; 95%CI 0.88–1.26, p=0.55) and in ICH (OR: 1.16; 95%CI 0.75–1.81; p=0.49) was observed. Increased potency of P2Y 12 -receptor inhibition is associated with decreased risk in cardiovascular death and MI; however, this association is not true in case of stroke, where potent P2Y 12 -receptor antagonists have no incremental benefit over clopidogrel.

Keywords

Stroke, clopidogrel, platelet inhibition, prasugrel, ticagrelor, P2Y 12 -receptor

DOI

http://dx.doi.org/10.1160/TH12-06-0377

You may also be interested in...

1.

Online Supplementary Material

C. B. Olivier (1), P. Diehl (1), K. Schnabel (1), P. Weik (1), Q. Zhou (1), C. Bode (1), M. Moser (1)

Thromb Haemost 2014 111 2: 266-272

http://dx.doi.org/10.1160/TH13-06-0508

2.

Online Supplementary Material

N. Straub (1), A. Beivers (2), E. Lenk (3), D. Aradi (4), D. Sibbing (5)

Thromb Haemost 2014 111 2: 290-299

http://dx.doi.org/10.1160/TH13-08-0679

3.

See also Editorial by Huber, Lip

V. L. Serebruany (1), J. J. DiNicolantonio (2)

Thromb Haemost 2013 110 1: 5-10

http://dx.doi.org/10.1160/TH13-02-0142



Thrombosis News

Mobile technology identifies people with unknown atrial fibrillation at high risk of stroke – article published in Thrombosis and Haemostasis

The article “Feasibility and cost effectiveness of stroke prevention through community screening...

TH 111.4

The April 2014 TH 111.4 issue of Thrombosis and Haemostasis is a Theme Issue by Guest Editor B....

TH 111.3

Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...